Zobrazeno 1 - 10
of 37
pro vyhledávání: ''
Autor:
Margaret M. Kozak, Frederick M. Dirbas, Emily Walck, Rie von Eyben, Clare E. Jacobson, Kathleen C. Horst, Paulina M. Gutkin
Publikováno v:
Clinical Breast Cancer. 20:431-438
Background Optimal surgical management of limited axillary nodal disease following neoadjuvant chemotherapy (NAC) for breast cancer is evolving. Concerns exist with respect to leaving residual disease in the axilla when omitting axillary lymph node d
Autor:
Stephanie Dille, Richard A. Hansen, Johanna Harde, Karin Potthoff, Oliver Stötzer, Norbert Marschner, Ulrike Söling, Arnd Nusch
Publikováno v:
Clinical Breast Cancer. 20:e315-e326
Background There are only scarce data on treatment of elderly patients with nab-paclitaxel for metastatic breast cancer, especially from the real-world setting. Here we present data from the noninterventional study NABUCCO with special focus on taxan
Autor:
Eustratios Bananis, Miguel Martin, Richard S. Finn, Aurelio Castrellon, Anil Abraham Joy, Eric Gauthier, Hirofumi Mukai, Janice M. Walshe, Hope S. Rugo, A. Mori, D. Lu, Nadia Harbeck, Karen A. Gelmon, Véronique Diéras
Publikováno v:
Clinical Breast Cancer. 20:e173-e180
Background In PALOMA-2, palbociclib + letrozole significantly prolonged progression-free survival (PFS) versus placebo + letrozole in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2−) advanced br
Autor:
Robert Wesolowski, Junan Li, Raquel E. Reinbolt, Bhuvaneswari Ramaswamy, Jonathan Wilkie, Craig A. Vargo, Sagar Sardesai, Anne M. Noonan, Michael Berger, M. Alexandra Schickli, Nicole Williams, Maryam B. Lustberg, Daniel G. Stover, Jeffrey VanDeusen
Publikováno v:
Clinical Breast Cancer. 20:33-40
Background Additional use of cyclin-dependent kinase 4/6 inhibitors with endocrine therapy improves progression-free survival (PFS) in advanced hormone receptor (HR)-positive HER2-negative breast cancer. However, neutropenia is a common reason for do
Publikováno v:
Clinical Breast Cancer. 20:e82-e88
Background Clinical response evaluation by image examination after neoadjuvant chemotherapy for breast cancer is important for determining drug response and progression. Mammography is less correlated with pathologic response assessment than magnetic
Autor:
Ritu Aneja, Zhimin Wei, Jane L. Meisel, Xiaoxian Li, Rita Nahta, Aili Suo, Chao Zhang, Ruth O'Regan, Jing Zhao, Caitlin E. Taylor, Zaibo Li, Uma Krishnamurti
Publikováno v:
Clinical Breast Cancer. 20:19-24
Background HER2-targeted neoadjuvant therapy has high efficacy in treating HER2-positive breast cancer. Response to neoadjuvant therapy helps clinicians make treatment decisions and make estimates about prognosis. This study examined clinicopathologi
Autor:
Zhe Wang, Guangdong Hou, Juliang Zhang, Rui Ling, Ying Wu, Jingjing Xiao, Niuniu Hou, Lili Guo
Publikováno v:
Clinical breast cancer. 20(6)
To explore the independent predictors of pathologic complete remission response (pCR) for Chinese patients with breast cancer (BC) after preoperative chemotherapy and to develop an individualized nomogram for predicting the probability of pCR.The cli
Autor:
Marcella Mottolese, Anna Di Benedetto, Claudio Botti, Alessandra Fabi, Cecilia Nisticò, Patrizia Vici, Cristiana Ercolani, Paola Malaguti, Michelangelo Russillo, Edoardo Pescarmona, Letizia Perracchio, Simonetta Buglioni, Francesca Sperati, Gianluigi Ferretti, Francesco Cognetti, Irene Terrenato
Publikováno v:
Clinical breast cancer. 20(6)
p53 and antiapoptotic B-cell leukemia/lymphoma 2 (BLC2) have been proposed as prognostic markers for early breast cancer (BC), although their relationship with conventional parameters and patient prognosis, as well as their distribution within the mo
Autor:
Robert W. Mutter, Sarah S. Mougalian, Heather B. Neuman, Charles L. Loprinzi, Rachel A. Freedman, Alexis D. Leal, Tufia C. Haddad, Ahmedin Jemal, Lindsey R. Sangaralingham, Kathryn J. Ruddy, Holly K. Van Houten, Cary P. Gross, Nilay Shah, Theresa H.M. Keegan
Publikováno v:
Clinical breast cancer, vol 18, iss 4
BackgroundTreatment-related toxicity can vary substantially between chemotherapy regimens. In this study we evaluated the frequency of outpatient office visits among a cohort of early stage breast cancer survivors after completion of 4 different adju
Autor:
Y Liu, Raymond C. Bergan, Yueping Liu, Xiangmei Zhang, Zhenzhen Zhang, Motomi (Tomi) Mori, Miao Cao, Shiuh Wen Luoh, Beichen Liu
Publikováno v:
Clinical breast cancer. 20(4)
Background To explore the potential advantage of preoperative anti-angiogenosis therapy, we implemented a study to evaluate the efficacy of recombinant human endostatin (EN) in combination with neoadjuvant chemotherapy in the treatment of stage III b